The estimated Net Worth of John P. Butler is at least $7.94 Million dollars as of 29 February 2024. Mr. Butler owns over 46,570 units of Akebia Therapeutics stock worth over $2,944,195 and over the last 11 years he sold AKBA stock worth over $676,689. In addition, he makes $4,316,960 as President, Chief Executive Officer, and Director at Akebia Therapeutics.
John has made over 24 trades of the Akebia Therapeutics stock since 2014, according to the Form 4 filled with the SEC. Most recently he sold 46,570 units of AKBA stock worth $73,581 on 29 February 2024.
The largest trade he's ever made was exercising 287,000 units of Akebia Therapeutics stock on 3 June 2019 worth over $134,890. On average, John trades about 25,673 units every 84 days since 2014. As of 29 February 2024 he still owns at least 2,044,580 units of Akebia Therapeutics stock.
You can see the complete history of Mr. Butler stock trades at the bottom of the page.
John P. Butler serves as President, Chief Executive Officer, Director of the Company. Prior to joining Akebia, from 2011 until 2013, Mr. Butler served as the Chief Executive Officer of Inspiration Biopharmaceuticals, Inc., a company that filed for protection under Chapter 11 of the U.S. Bankruptcy Code in October 2012 prior to the successful sale of its hemophilia assets to Cangene Corporation and Baxter International in early 2013 for total aggregate consideration that could exceed $1 billion. From 1997 to 2011, Mr. Butler held various positions at Genzyme Corporation, now Sanofi Genzyme, most recently serving as President of the company’s rare genetic diseases business. From 2002 until 2010, Mr. Butler led Genzyme’s renal division. Prior to his work at Genzyme, Mr. Butler held sales and marketing positions at Amgen and Hoffmann-La Roche. Mr. Butler currently serves on the Board of Directors of Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE). From 2013 to 2016, Mr. Butler served on the Board of Directors of Relypsa, Inc. From 2015 to 2017, Mr. Butler served on the Board of Directors of Keryx and was Chairman of Keryx’s Board of Directors from 2016 to 2017. Mr. Butler is the Chairperson of Kidney Care Partners and formerly served as a Chairman of the Board of Trustees of the American Kidney Fund. Mr. Butler received a B.A. in Chemistry from Manhattan College and an M.B.A. degree from Baruch College, City University of New York.
As the President, Chief Executive Officer, and Director of Akebia Therapeutics, the total compensation of John Butler at Akebia Therapeutics is $4,316,960. There are no executives at Akebia Therapeutics getting paid more.
John Butler is 55, he's been the President, Chief Executive Officer, and Director of Akebia Therapeutics since 2013. There are 8 older and 11 younger executives at Akebia Therapeutics. The oldest executive at Akebia Therapeutics Inc. is Adrian Adams, 69, who is the Independent Chairman of the Board.
John's mailing address filed with the SEC is C/O AKEBIA THERAPEUTICS, INC., 245 FIRST STREET, CAMBRIDGE, MA, 02142.
Over the last 11 years, insiders at Akebia Therapeutics have traded over $3,056,393 worth of Akebia Therapeutics stock and bought 2,141,907 units worth $27,915,834 . The most active insiders traders include Holdings A/S Novo, Muneer A Satter, and Mark J Enyedy. On average, Akebia Therapeutics executives and independent directors trade stock every 28 days with the average trade being worth of $43,534. The most recent stock trade was executed by Nicole R. Hadas on 13 May 2024, trading 12,016 units of AKBA stock currently worth $15,140.
akebia therapeutics, inc. is a biopharmaceutical company headquartered in cambridge, massachusetts, focused on delivering innovative therapies to patients with kidney disease through hypoxia-inducible factor (hif) biology. akebia’s lead product candidate, vadadustat, is an investigational oral therapy in development for the treatment of anemia related to chronic kidney disease in both non-dialysis and dialysis patients. akebia’s global phase 3 program for vadadustat, which includes the pro2tect studies for non-dialysis patients with anemia associated with chronic kidney disease and the inno2vate studies for dialysis-dependent patients, is currently ongoing. for more information, please visit our website at www.akebia.com.
Akebia Therapeutics executives and other stock owners filed with the SEC include: